Gold Fields Limited vs Revvity Inc — how do they compare? Gold Fields Limited trades at $36.9 (market cap $31.87B), while Revvity Inc trades at $154.75 (market cap $16.98B). The key difference: Gold Fields Limited is the larger of the two by market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Revvity Inc for 12 Days on average.
| GFI | RVTY | |
|---|---|---|
Market Cap | $31.87B | $16.98B |
Volume | 4,169,651 | 1,456,900 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $157.36 |
52-Week Low | $31.25 | $82.26 |
Typical Hold Time | 49 Days | 12 Days |
Enterprise Value | $32.47B | $19.30B |
Dividend Yield | 6% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.70, up 4.71% over 24 hours, but technical indicators signal a bearish trend with price near support at $35. The company reported strong 2025 results with revenue of $8.75 billion and net income of $3.57 billion, yielding high profitability margins. However, recent earnings misses and a rejected $27 billion takeover bid for Northern Star have introduced volatility. Analyst consensus remains positive with a $52.75 price target, but the stock faces headwinds from acquisition-related uncertainty and mixed technical signals.
GFI presents a compelling value case with low P/E of 7.3 and robust cash flow growth, but investors must weigh execution risks from its aggressive M&A strategy and recent earnings inconsistencies against its strong fundamentals and shareholder returns. The stock's near-term direction hinges on merger outcomes and gold price stability.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →